Previous Article | Next Article ![]()
Journal of Virology, July 2001, p. 6016-6021, Vol. 75, No. 13
Department of Biochemistry, Case Western
Reserve University School of Medicine, Cleveland, Ohio
44106-49351; Pennsylvania State
University College of Medicine, Hershey, Pennsylvania
170332; and Northwestern University
School of Medicine, Chicago, Illinois 606113
Received 27 September 2000/Accepted 9 April 2001
The formation of the mature carboxyl terminus of CA in avian
sarcoma/leukemia virus is the result of a sequence of cleavage events
at three PR sites that lie between CA and NC in the Gag polyprotein.
The initial cleavage forms the amino terminus of the NC protein and
releases an immature CA, named CA1, with a spacer peptide at its
carboxyl terminus. Cleavage of either 9 or 12 amino acids from the
carboxyl terminus creates two mature CA species, named CA2 and CA3,
that can be detected in avian sarcoma/leukemia virus (R. B. Pepinsky, I. A. Papayannopoulos, E. P. Chow, N. K. Krishna, R. C. Craven, and V. M. Vogt, J. Virol.
69:6430-6438, 1995). To study the importance of each of the three CA
proteins, we introduced amino acid substitutions into each CA cleavage
junction and studied their effects on CA processing as well as virus
assembly and infectivity. Preventing cleavage at any of the three sites produced noninfectious virus. In contrast, a mutant in which cleavage at site 1 was enhanced so that particles contained CA2 and CA3 but
little detectable CA1 was infectious. These results support the idea
that infectivity of the virus is closely linked to proper processing of
the carboxyl terminus to form two mature CA proteins.
The structural proteins and enzymes
of retroviruses are synthesized as part of Gag or Gag-Pol polyproteins.
Late in the viral life cycle these polyproteins, along with viral
envelope proteins and genomic RNA, aggregate at the cell membrane to
form and subsequently bud immature virus particles. These immature
viral particles are characterized by electron-lucent centers when
examined by electron microscopy. Proteolytic processing of the Gag and
Gag-Pol polyproteins by the virus-encoded protease yields mature
structural proteins and enzymes (for a review, see reference
19). For specific cleavage, the PR recognizes an
eight-amino-acid sequence symmetrically placed around the cleavage
junction (17). Proteins processed from the avian
sarcoma/leukemia virus (ASLV) Gag polyprotein include MA, p10, CA, NC,
and PR. In addition, a 22-amino-acid sequence between MA and p10
contains a PPPPYV sequence, termed the L assembly domain, required for a step late during the viral budding process (21, 24). There are also a small number of amino acids between CA and
NC, and these are referred to as the spacer (SP) region. Deletion of
the SP results in the loss of virus infectivity (6, 15). Similar deletions in human immunodeficiency virus type 1 (HIV-1) Gag
produce noninfectious virus (13, 16).
When Rous sarcoma virus (RSV) Gag is expressed in various cell types,
three CA-containing species are resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (6). The bands are named according to their relative migration position; the
fastest-migrating band is termed CA1, the middle band is CA2, and the
slowest band is CA3 (6). CA1 is the first CA-containing band that appears and results from cleavage at Met488 (see Fig. 1). It
is replaced over time with the appearance of CA2 and CA3. The
sequential appearance of the three CA-containing proteins results from
PR cleavage at three sites at the boundary of CA and NC in Gag. In
mature ASLV, more than 90% of the CA-containing protein is accounted
for as CA2 and CA3. A mass spectroscopy analysis of these two forms of
CA indicates that they share a common amino terminus (15).
Their carboxyl termini were mapped to Met479 and Ala476. In this
report, we show that preventing cleavage at any of the three
carboxyl-terminal CA sites results in noninfectious virus. In contrast,
a mutant that has CA2 and CA3 proteins with little CA1 was infectious.
This suggests that infectious virus is dependent upon proper processing
to form these two mature CA proteins.
Reagents.
All reagents were as previously described
(21). Oligodeoxynucleotides were purchased from
Midland Certified Reagent Company (Midland, Tex.) and used directly for
mutagenesis. The wild-type RSV gag gene is from pATV-8, an
infectious molecular clone of the RSV Prague C strain. The plasmid
pSV.Myr0 is a simian virus 40-based mammalian expression vector
carrying a wild-type copy of the RSV gag allele, the product
of which efficiently directs production of virus-like particles from
COS-1 cells (22).
Oligodeoxynucleotide-directed mutagenesis.
Site-directed
mutagenesis of the RSV gag gene was carried out by overlap
extension mutagenesis as described by Aiyar et al. (2). In
most cases, the mutations create a new restriction enzyme site to
facilitate identification of clones containing the desired mutation.
The oligodeoxynucleotides used to introduce mutations are listed in
Table 1.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.6016-6021.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Proper Processing of Avian Sarcoma/Leukosis Virus
Capsid Proteins Is Required for Infectivity

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Mutagenic oligodeoxynucleotides
Transfection of mammalian cells. COS-1 cells grown in Dulbecco's modified Eagle's medium supplemented with 3% fetal bovine serum and 7% calf serum (Hyclone Inc.) were transfected by the Lipofectamine Plus method (7) (Gibco-BRL). Plasmid DNAs, at a concentration of 25 µg/ml, were digested with XbaI and incubated with T4 DNA ligase before transfection. This removes the bacterial plasmid sequence and joins the 3' end of the gag gene with the simian virus 40 late polyadenylation signal (22).
Metabolic labeling and immunoprecipitations. In most experiments, cells in 35-mm dishes were labeled 48 h after transfection with L-[35S]methionine (1,000 Ci/mmol, 75 µCi/ml of tissue culture medium) for 2.5 h at 37°C as described previously (22). The cells or growth medium from each labeled culture were mixed with lysis buffer containing protease inhibitors. Rabbit antiserum directed against whole RSV (reactive with MA, CA, NC, and PR Gag proteins) was added and immunoprecipitation carried out for 2.5 h at 4°C. Precipitates was collected using protein A-agarose (Gibco-BRL) and the proteins were subjected to electrophoresis (24). Pulse-labeling experiments were carried out with sets of identically transfected cells incubated in methionine-free medium for 30 min, labeled with [35S]methionine for 15 min, and chased with a 1,000-fold excess cold methionine in serum-free medium for the indicated times. Immunoprecipitated proteins were separated by electrophoresis through a SDS-polyacrylamide gel (13%) and detected by fluorography as previously described (22). Overnight exposures were typically required.
Coupled transcription and translation of CA proteins. Vectors for expression of each of the three CA proteins were constructed by PCR amplification of the CA coding sequence using NTCAXhol (17) and one of each of the 6HXAHTCAP oligodeoxyribonucleotides: NTCAXhol, 5'TACTCGAGATGCCTGTAGTGAAATTAAGACAGAG3'; 6HXAHTCAPa, 5'CTCTCTCTGTTAAGCTTCTACATAATTAAGGGCTGGAT3'; 6HXAHTCAPb, 5'TAAGGACTGGTTAAGCTTCTACATGGCCGCGGCTATG3'; and 6HXAHTCAPc, 5'CTGGATGACAGACACAAGCTTCTAGGCTATGC3' (italics indicate the HindIII sites, boldface indicates stop codons, and underlines indicate the start codon).
6HXAHTCAPa terminates the CA coding sequence at Met488, 6HXAHTCAPb terminates the CA coding sequence at Met479, 6HXAHTCAPc terminates the CA coding sequence at Ala476. The amplified fragments were cloned into pBC SK+ (Stratagene) in an orientation allowing in vitro transcription from a T7 promoter. Proteins were synthesized using the TNT quick coupled transcription-translation system (Promega) as described by the manufacturer.Virus infectivity. An evaluation of virus infectivity was made by testing the ability of wild-type and mutant viruses to establish a persistent infection after transfection of DNA bearing the mutant viral genomes into susceptible cells. The proviral DNAs were introduced into duplicate 65-mm dishes of quail (QT6) cells by calcium phosphate-mediated transfection. To confirm successful transfection, the first plate of each pair was radiolabeled with [35S]methionine at 18 h posttransfection. Then the CA protein, Gag, and CA-related cleavage intermediates were immunoprecipitated from lysates and medium samples with anti-CA serum and analyzed as described previously (6, 22). The second plate of cells was serially passaged at approximately 3-day intervals. The persistence of the mutant viruses was tested at passages 3 through 6 either by immunoprecipitation of radiolabeled antigens from lysates and medium samples with anti-CA or by Western blotting of CA antigens pelleted from the culture medium.
| |
RESULTS |
|---|
|
|
|---|
Altering polyprotein cleavage at the CA C terminus.
Previously, the analysis of deletion mutants of the SP region suggested
that CA1, CA2, and CA3 resulted from cleavage at Met488, Ala476, and
Met479, respectively (Fig. 1). We have
confirmed this assignment by analyzing the migration patterns of
in vitro-translated recombinant CA proteins that terminated
at these three positions (data not shown). We therefore use CA1, CA2,
and CA3 (as originally defined by Craven et al. [6]) to
indicate capsid proteins terminating at Met488, Ala476, and Met479,
respectively. We refer to the CA cleavage sites to form CA1, CA2, and
CA3 as sites 1, 2, and 3, respectively (Fig. 1).
|
|
The stable accumulation of CA1 is not required for infectious virus. The effects of altered CA processing on viral infectivity were examined by subcloning each of the above mutations into the RCAN virus vector and determining if infectious virus could be recovered after transfection of the DNA into quail cells. These results are summarized in Fig. 1. While persistent infection was detected for wild-type virus after three or six passages, no viral protein was detected either in cells or in the medium after the passage of mutants that were altered in the processing of site 1, indicating that these mutant viruses were noninfectious (Fig. 1). All mutations that were designed to decrease the cleavage rates of site 2, site 3, or both (Fig. 1) caused a similar block to infection. In contrast, persistent infection resulted after three passages of cells expressing a clone with the A477L substitution (data not shown). Since little CA1 is detected in the A477G,M479G mutant, these results suggest that the length of time that CA1 persists is not important for infectivity, although its transient presence maybe needed for formation of CA2 and CA3.
Efficient cleavage to form CA2 and CA3 may require prior processing
at downstream site 1.
While infectious virus is obtained with an
A477L mutant where little CA1 is evident, completely preventing the
formation of CA1 in the L486G, M488G mutant results in noninfectious
virus. This raises the possibility that cleavage at site 1 may
facilitate the cleavage at upstream sites 2 and 3 similar to that of
HIV-1 CA processing (20). In examining the results with
the L486G,M488G mutant, we noticed that while the CA1 band was
completely absent, the apparent amounts of CA2 and CA3 bands detected
were reduced compared to those obtained with the wild type (Fig. 2A,
compare media, lanes 1 and 2). Also, in the medium fraction, there were additional Gag intermediates migrating between Gag and the mature CA1,
CA2, and CA3 bands not present in the wild type. Therefore we carried
out a pulse-chase-type experiment (Fig.
3) to assess the relative cleavage rates
at CA junctions. In the lysate fraction, the wild-type gag
allele released CA1 during a 15-min labeling. With the A477G,M479G
mutant, a band appeared as rapidly as CA1 in the wild type and in
normal amounts compared to the wild type, even though the CA2 and CA3
bands were not present (Fig. 3). The L486G, M488G mutant did not
release any CA proteins until after a 60-min incubation in the presence
of excess unlabeled methionine. In addition, there were bands migrating
between Gag and CA in the lysate during the chase. These results
clearly demonstrate that processing at the upstream site 2 and 3 occurred much later than processing at site 1. They also suggest that
efficient cleavage to form CA2 and CA3 may require prior cleavage to
form CA1.
|
L domain and CA processing.
The RSV L assembly domain consists
of a small proline-rich sequence that maps to the p2 region of Gag and
is required for efficient budding of virus from cells (21,
24). Previously, when studying mutations in the L domain, we
noticed that there was a correlation between the budding of viral
particles from cells and the extent of processing at the CA-SP-NC
cleavage sites (24). For instance, cleavage was observed
almost exclusively at the CA1 site in cell lysates where the L domain
was deleted from Gag (Fig. 4, Lysates,
lane 4). To explore the possibility that the processing at the upstream
sites 2 and 3 is dependent upon particle release, the A477L mutant was
combined with an L domain deletion mutant. Two CA proteins whose
migration corresponds to CA1 and CA3 were detected in the cell lysate
expressed from the combined L domain A477L mutant (Fig. 4, Lysates,
lane 2). This is in contrast to observing only CA1 in cell lysates from the L domain mutant (21, 24) and both CA2 and CA3 with the A477L mutant. This result shows that Gag particle release is not absolutely required for processing CA1 to CA3. However, the release of
CA2 may still require the budding process to occur.
|
| |
DISCUSSION |
|---|
|
|
|---|
The presence of a spacer peptide between CA and NC in Gag is a conserved feature common to avian retroviruses and lentiviruses. Despite the lack of significant sequence identity between the respective HIV-1 and RSV CA and spacer sequences, proteolytic processing of this region is remarkably similar for both and occurs in a stepwise manner. Previously, it was shown that cleavage of the upstream HIV-1 CA site was reduced by the abolishment of the downstream CA site (20). In this report, we demonstrate that when cleavage of the RSV downstream CA site 1 was prevented, in the L486G,M488G mutant, the amounts of mature CA proteins resulting from cleavage at the upstream sites 2 and 3 were also reduced. Both the L486G,M488G and the A489L mutant, which has a single amino acid substitution in site 1, produce noninfectious virus. Additionally, these mutants show Gag processing intermediates that are absent in the wild type. We believe that these intermediates resulted from a delayed processing at CA junctions. However, it is also possible that amino acid substitutions at site 1 may cause a portion of Gag to improperly fold or somehow become refractory to further cleavage. It is conceivable that these intermediates might interfere with the correct assembly of virions. In addition, the L486G,M488G mutation would almost certainly alter the structure of the NC, and this change might contribute to the infectivity defect of this mutant.
The removal of the spacer peptide from immature CA was previously shown to be important for HIV-1 assembly (20). The RSV A477G,M479G mutant, which produces only immature CA, is noninfectious. However, since the A477G,M479G mutant introduces changes in the CA coding sequence as well as changes the cleavage sites, we cannot exclude the possibility that the replication defect is caused by an altered CA protein. The L domain deletion mutant also shows CA2 and CA3 processing defects that can be partially rescued by increasing the cleavage rate of these two sites with the A477L substitution. Nevertheless, these viruses are noninfectious. This is not surprising, since the A477L substitution would not correct the budding defect caused by a loss in L-domain function.
CA1 exists transiently for periods of time after the release of particles from cells (Fig. 4). Similarly, in HIV-1, a CA protein containing the spacer peptide, called CA-p2 or CA-SP1, exists transiently as a result of the low rate of cleavage of the CA-SP1 site. RSV CA1 and HIV-1 CA-SP1 may play a role in early events of particle assembly, since deletion of the spacer sequences result in the production of noninfectious viruses (6, 15). In the A477L mutant, little CA1 was detected, consistent with a shorter-than-normal half-life for this cleavage intermediate. It was therefore interesting to find that the A477L mutant was infectious. Bowzard et al. (2a) have confirmed this result with the finding that a substitution of Leu for Ser480 in a gag allele also produces infectious virus. This mutation is predicted to increase the rate of cleavage to form CA2 and CA3 similarly to the A477L mutant. Like the A477L substitution, this mutation caused the rapid appearance of the mature CA species, presumably due to enhanced cleavage at sites 2 and 3, and allowed full infectivity. Although we cannot eliminate the importance of CA1 for viral replication, these results suggest that the length of time CA1 persists is not essential for the viral life cycle.
In our SDS-PAGE analysis, we noticed that the immature CA1 protein migrates unusually rapidly, consistent with the observations of Pepinsky et al. (15). Gel electrophoresis analysis of the CA bands obtained from mutant proteins that bear single or double amino acid substitutions has located the region responsible for the aberrant migration to that around cleavage sites 2 and 3. The mutants with Gly substitutions at positions 475, 477, and 479 showed a loss of the three normal bands and the appearance of a novel band. Pepinsky et al. (15) also observed that a deletion of the amino acids Ala, Ala, and Met from positions 477 to 479 resulted in a change in migration of the detected CA-containing bands. We speculate that the Gag region between 475 and 481 may be associated with changes in the residual structure of CA in SDS. Alternatively, the substitutions themselves may be responsible for the change in migration of the bands. We believe that this is unlikely because of the very small size of the region where substitutions result in changes in migration.
The structures of the entire RSV CA protein (5) and the
C-terminal domain of RSV CA with and without the 12-amino-acid spacer
peptide attached (12) have been determined by nuclear magnetic resonance spectroscopy. In each case, the very end of the CA
protein from the Pro at Gag position 469 through the spacer peptide was
found to be disordered or to exist in multiple conformations. The
addition of the spacer peptide to the C-terminal domain caused no
obvious change in either the C terminus of CA or the remainder of the
C-terminal domain. A similar situation has been described for the HIV-1
CA protein (12, 23). However, Accola et al. (1) have reported the prediction of an
-helix in the
CA-p2 boundary in HIV-1 Gag. Moreover, HeLa cells transfected with
proviral DNA containing amino acid substitutions that should disrupt
this predicted
-helix produced heterogeneous particles. Conversely, amino acid substitutions at the same site predicted to maintain the
-helix structure produced homogeneous particles with a cone-shaped core similar to mature HIV-1 particles (1). This suggests
that the peptides, p2 for HIV and presumably SP for RSV, form a helical structure in the CA-NC cleavage intermediate. Deletions in the CA or SP
regions of RSV Gag lead to the production of heterogeneously sized
particles (14). The changes in migration of RSV Gag
peptides with mutations in and around sites 2 and 3 described in this
report would be consistent with the different CA species having
different conformations, although this has not been found in existing
structural studies (5, 12). In another study of the
in vitro assembly of HIV-1 CA, the spacer peptide was also
found to alter the conformation and packing of CA subunits in assembled
particles (11). Thus, it is possible that the
three-dimensional structures of purified CA proteins as now reported
may not represent the full range of conformations that these proteins
adopt in particles. It is possible, for instance, that the spacer
peptide in CA1 becomes structured when it is assembled into
higher-order arrays.
A model of retrovirus core assembly has suggested that the cores of all retroviruses could be composed of closed hexagonal lattices made from CA proteins (8). It is conceivable that the two forms of mature RSV CA fit into different structural environments in an assembled core. Therefore, the loss of one form or the dramatic alteration of the ratio of the mature forms would be expected to compromise the core structure and possibly viral replication. In the A477L mutant, the ratio of the two CA proteins was different from that of the wild type. This result does not invalidate this model, since one of the two forms of CA may be needed only in small amounts. A better understanding must await determination of high-resolution structures of the assembled cores.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by research grants CA 52047 (J.L.), CA 38046 (J.L.), and CA47482 (R.C. [co-PI]) from the National Cancer Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, Northwestern University School of Medicine, 303 E. Chicago Ave., Chicago, IL 60611. Phone: (312) 503-0338. Fax: (312) 503-7654. E-mail: j-leis{at}northwestern.edu.
Present address: NIH/NIAID/LVD, Bethesda, MD 20892-0445.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Accola, M. A.,
S. Höglund, and H. G. Göttlinger.
1998.
A putative -helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly.
J. Virol.
72:2072-2078 |
| 2. | Aiyar, A., Y. Xiang, and J. Leis. 1996. Site-directed mutagenesis using overlap extension PCR. Methods Mol. Biol. 57:177-191[Medline]. |
| 2a. | Bowzard, J. B., J. W. Wills, and R. C. Craven. Second-site suppressors of Rous sarcoma virus CA mutations: evidence for interdomain interactions. J. Virol., in press. |
| 3. |
Cameron, C.,
B. Grinde,
P. Jacques,
J. Jentoft,
A. Wlodawer,
I. Weber, and J. Leis.
1993.
Comparison of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus, type 1 protease.
J. Biol. Chem.
268:11711-11720 |
| 4. |
Cameron, C. E.,
T. W. Ridky,
S. Shulenin,
J. Leis,
I. T. Weber,
T. Copeland,
A. Wlodawer,
H. Burstein,
D. Bizub-Bender, and A. M. Skalka.
1994.
Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
J Biol. Chem.
269:11170-11177 |
| 5. | Campos-Olivas, R., J. L. Newman, and M. F. Summers. 2000. Solution structure and dynamics of the Rous sarcoma virus capsid protein and comparison with capsid proteins of other retroviruses. J. Mol. Biol. 296:633-649[CrossRef][Medline]. |
| 6. |
Craven, R. C.,
A. E. Leure-duPree,
C. R. Erdie,
C. B. Wilson, and J. W. Wills.
1993.
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein.
J. Virol.
67:6246-6252 |
| 7. | Felgner, J., F. Bennett, and G. Feilgner. 1993. Cationic lipid-mediated delivery of polynucleotides. Methods 5:67[CrossRef]. |
| 8. |
Ganser, B. K.,
S. Li,
V. Y. Klishko,
J. T. Finch, and W. I. Sundquist.
1999.
Assembly and analysis of conical models for the HIV-1 core.
Science
283:80-83 |
| 9. |
Grinde, B.,
C. Cameron,
I. Weber,
A. Wlodawer,
H. Burstein,
D. Bizub,
A. M. Skalka, and J. Leis.
1992.
Mutations that alter the activity of the Rous sarcoma virus protease.
J. Biol. Chem.
267:9481-9490 |
| 10. |
Grinde, B.,
C. Cameron,
I. Weber,
A. Wlodawer,
H. Burstein,
A. M. Skalka, and J. Leis.
1992.
Analysis of substrate interactions of the Rous sarcoma virus and human immunodeficiency virus-1 proteases using a set of systematically altered peptide substrates.
J. Biol. Chem.
267:9491-9498 |
| 11. | Gross, I., H. Hohenberg, T. Wilk, K. Wiegers, M. Grattinger, B. Muller, S. Fuller, and H. G. Krausslich. 2000. A conformational switch controlling HIV-1 morphogenesis. EMBO J. 19:103-113[CrossRef][Medline]. |
| 12. | Kingston, R. L., T. Fitzon-Ostendorp, E. Z. Eisenmesser, G. W. Schatz, V. M. Vogt, C. B. Post, and M. G. Rossmann. 2000. Structure and self-association of the Rous sarcoma virus capsid protein. Structure Fold Des. 8:617-628[Medline]. |
| 13. | Krausslich, H. G., M. Facke, A. M. Heuser, J. Konvalinka, and H. Zentgraf. 1995. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J. Virol. 69:3407-3419[Abstract]. |
| 14. |
Krishna, N.,
S. Campbell,
V. Vogt, and J. Willis.
1998.
Genetic determinants of Rous sarcoma virus particle size.
J. Virol.
72:564-577 |
| 15. | Pepinsky, R. B., I. A. Papayannopoulos, E. P. Chow, N. K. Krishna, R. C. Craven, and V. M. Vogt. 1995. Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J. Virol. 69:6430-6438[Abstract]. |
| 16. |
Pettit, S. C.,
M. D. Moody,
R. S. Wehbie,
A. H. Kaplan,
P. V. Nantermet,
C. A. Klein, and R. Swanstrom.
1994.
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.
J. Virol.
68:8017-8027 |
| 17. |
Ridky, T.,
D. Bizub-Bender,
C. Cameron,
I. Weber,
A. Wlodawer,
T. Copeland,
A. M. Skalka, and J. Leis.
1996.
Programming the Rous sarcoma virus protease to cleave new substrate sequences.
J. Biol. Chem.
271:10538-10544 |
| 18. | Ridky, T., A. Kikonyogo, J. Leis, S. Gulnik, T. Copeland, J. Erikson, A. Wlodawer, I. Kurinov, R. Harrison, and I. Weber. 1998. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37:13835-13845[CrossRef][Medline]. |
| 19. | Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly and processing of viral proteins, p. 263-334. In J. M. Coffin, S. P. Hughes, and H. E. Varmus (ed.), Retroviruses, vol. 1. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 20. |
Wiegers, K.,
G. Rutter,
H. Kottler,
U. Tessmer,
H. Hohenberg, and H. G. Krausslich.
1998.
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.
J. Virol.
72:2846-2854 |
| 21. |
Wills, J. W.,
C. E. Cameron,
C. B. Wilson,
Y. Xiang,
R. P. Bennett, and J. Leis.
1994.
An assembly domain of the Rous sarcoma virus Gag protein required late in budding.
J. Virol.
68:6605-6618 |
| 22. |
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus Gag protein in mammalian cells.
J. Virol.
63:4331-4343 |
| 23. | Worthylake, D. K., H. Wang, S. Yoo, W. I. Sundquist, and C. P. Hill. 1999. Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr. D55:85-92[CrossRef]. |
| 24. |
Xiang, Y.,
C. E. Cameron,
J. W. Wills, and J. Leis.
1996.
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.
J. Virol.
70:5695-5700 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»